OncoMatch/Clinical Trials/NCT07501559
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)
Is NCT07501559 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies JL15003Injection for recurrent glioblastoma multiforme(gbm).
Treatment: JL15003Injection — The goal of this clinical trial is to evaluate the safety and efficacy of JL15003 Injection in subjects with recurrent glioblastoma (rGMB).
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Must have received: standard-of-care therapy (surgical resection, radiotherapy, temozolomide)
Refractory or relapsed following standard-of-care therapy or intolerance to standard therapy (surgical resection followed by radiotherapy and concurrent/adjuvant temozolomide)
Cannot have received: antitumor therapy (chemotherapy, targeted therapy, immunotherapy, TTFields, other investigational antitumor drugs)
Patients who have received antitumor therapy (including but not limited to chemotherapy, targeted therapy, immunotherapy, TTFields, or other investigational antitumor drugs) within 4 weeks prior to the first dose of the study drug or within 5 half-lives of the previous drug (whichever is longer), and has not recovered from the toxicities (i.e., to <= Grade 1 per CTCAE v5.0, except for alopecia; peripheral neuropathy up to Grade 2 is acceptable)
Cannot have received: radiation therapy
Exception: excluding those who have undergone radiation therapy for progressive diseases outside the radiation area
Patients who have received radiation therapy within 12 weeks prior to the administration of the investigational drug, excluding those who have undergone radiation therapy for progressive diseases outside the radiation area
Lab requirements
Blood counts
Hemoglobin <90g/L; Platelet count <100×10^9/L; Neutrophil count <1.5×10^9/L
Kidney function
Creatinine > 1.5 × upper limit of normal (ULN)
Liver function
Serum total bilirubin (TBIL) > 1.5×ULN; AST/ALT> 2.5×ULN
Cardiac function
Unstable or severe intercurrent medical conditions such as severe heart (NYHA Class 3 or 4); history of vascular diseases (including myocardial infarction, unstable angina pectoris, cerebrovascular disease, peripheral arterial disease, or aortic disease, etc.) within 6 months; uncontrolled hypertension (systolic blood pressure >= 160 mmHg or diastolic blood pressure >= 100 mmHg on at least 2 separate occasions, despite antihypertensive medication)
The laboratory tests meet the following standards: (1) Hemoglobin <90g/L; (2) Platelet count <100×10^9/L; (3) Neutrophil count <1.5×10^9/L; (4) Creatinine > 1.5 × upper limit of normal (ULN); (5) Serum total bilirubin (TBIL) > 1.5×ULN; (6) AST/ALT> 2.5×ULN; (7) Prothrombin and Partial Thromboplastin Times >1.2×ULN; Unstable or severe intercurrent medical conditions such as severe heart (NYHA Class 3 or 4); history of vascular diseases (including myocardial infarction, unstable angina pectoris, cerebrovascular disease, peripheral arterial disease, or aortic disease, etc.) within 6 months; uncontrolled hypertension (systolic blood pressure >= 160 mmHg or diastolic blood pressure >= 100 mmHg on at least 2 separate occasions, despite antihypertensive medication)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify